Mumbai: Homegrown private equity firm True North will acquire a minority stake in Embio Ltd, a regulated markets-focused manufacturer of Active Pharmaceutical Ingredients (APIs), True North announced on Wednesday.According to sources, True North invested about $50 million (₹478 cr) to acquire a 25% stake in Embio.The investment marks the third investment from True North’s Fund VII, and the first investment in the pharmaceuticals sector from this fund.The proceeds from this investment will largely be deployed toward R&D, and capacity expansion at Embio's upcoming manufacturing facility in Dahej, Gujarat and to scale the CDMO business.Embio is a manufacturer of complex APIs and intermediates with deep specialization in Synthetic Biology, integrating chemical and fermentation-based processes, alongside expertise in controlled substances, it said.The company’s portfolio spans multiple therapeutic areas, including nasal decongestants, ADHD, Parkinson’s disease, anti-epileptics, and anti-HIV drugs.Embio has a global customer base across more than 80 markets, including the United States, Europe, Japan, Brazil, Canada, Africa, and the Middle East.Satish Chander, Partner, True North, says, “Embio has established a strong position in complex APIs through its focus on technical excellence, long standing customer relationships in regulated markets, and a consistent focus on customer centricity and quality. We believe the Company is well-placed to play a meaningful role in India’s pharmaceutical manufacturing for global regulated markets."Devesh Malladi, Managing Director, Embio Ltd, added, “Their strong track record of partnering with high quality healthcare businesses and long-term approach makes them an ideal partner as we continue investing in technology, sustainability, and talent to position Embio as a leading Synthetic Biology based pharmaceutical company.”